How is SS-31 (Elamipretide / MTP-131) administered?
This describes how SS-31 (Elamipretide / MTP-131) is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once daily schedule, generally over 4-8 weeks. Specific dosing is individual and beyond general information, and human evidence for SS-31 (Elamipretide / MTP-131) is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once daily
- Cycle length: 4-8 weeks
- Half-life: ~2-4 hours
References
- Elamipretide in primary mitochondrial myopathy (MMPOWER trials) — Karaa A et al., Neurology, 2018
- Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER — Thompson WR, Manuel R, Abbruscato A, et al. — Genetics in Medicine, 2024
- FORZINITY (elamipretide hydrochloride) injection — FDA Prescribing Information — FDA / DailyMed (Stealth BioTherapeutics), 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on SS-31 (Elamipretide / MTP-131)
Full SS-31 (Elamipretide / MTP-131) breakdownSS-31 (Elamipretide / MTP-131) what it's used forSS-31 (Elamipretide / MTP-131) side effectsSS-31 (Elamipretide / MTP-131) mistakes to avoidSS-31 (Elamipretide / MTP-131) who should avoid itSS-31 (Elamipretide / MTP-131) half-lifeSS-31 (Elamipretide / MTP-131) how long to workSS-31 (Elamipretide / MTP-131) legal statusSS-31 (Elamipretide / MTP-131) how it worksAsk the AI Coach
Last updated 2026-06-15.